Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Full Speed Ahead: 5 Straight Months of Dow Gains

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

It's awfully tough to knock this market off track. Even after data today showed a surprising slowdown in U.S. business activity, Wall Street cheered on news that home prices and consumer confidence continued to rise. Though the Dow Jones Industrial Average's (DJINDICES: ^DJI  ) modest 21-point, 0.1% advance today isn't in itself anything to write home about, a fifth straight month of gains that has brought the index within reach of the 15,000 mark shows a determined bull market.

Technology stocks flexed their muscles for a second straight day, and International Business Machines (NYSE: IBM  ) ended as the top gainer, rising 1.7%. Shareholders cheered Big Blue's decision to boost its quarterly dividend by 12% this morning, a move that brought the annual payout to nearly 2%.

Microsoft (NASDAQ: MSFT  ) joined IBM shares in gains, adding 1.5% as it keeps its momentum from Monday's 2.6% surge. Yesterday's gains came as the company announced it reached the landmark $1 billion figure in annual revenues from cloud-related services. Today's gains are likely due to another development in the technology markets: Just after Microsoft's $1.95 billion bond offering last week, news of a $17 billion bond issuance by Apple today shows a confidence in the sector that should reassure shareholders.

While tech may be showing signs of renewed strength, the mood just got a bit bleaker in the health-care sector. Merck (NYSE: MRK  ) slipped 1.7% ahead of its earnings report tomorrow. As is often the case, the dive was due to a poor showing by its rival Pfizer (NYSE: PFE  )  today that gave investors the jeebies. Although some recent developments -- such as the companies' deal to work together on a new diabetes drug -- remain promising, Pfizer's earnings disappointment overshadows all of that. 

A brutal and sudden decline in patent protection for some of Pfizer's most lucrative drugs, combined with exchange-rate headwinds, caused Pfizer to lower expectations for the year. Shares tumbled 4.5% as a result, bringing Merck shares down with it. 

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2398476, ~/Articles/ArticleHandler.aspx, 9/30/2016 9:41:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 25 minutes ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 5:01 PM
^DJI $18308.15 Up +164.70 +0.91%
IBM $158.85 Up +0.74 +0.47%
IBM CAPS Rating: ****
MRK $62.41 Up +0.50 +0.81%
Merck and Co. CAPS Rating: ****
MSFT $57.60 Up +0.20 +0.35%
Microsoft CAPS Rating: ****
PFE $33.87 Up +0.55 +1.65%
Pfizer CAPS Rating: ****